Dow Jones

39,908.00

0.88%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Context Therapeutics Inc (CNTX)
Context Therapeutics Inc (CNTX) Noticias

CNTX

Context Therapeutics (CNTX)

Context Therapeutics Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CNTX

1 2 3 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
10/05/2024	15:00	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:CNTX	Context Therapeutics Inc
08/05/2024	15:06	GlobeNewswire Inc.	Context Therapeutics Reports First Quarter 2024 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
08/05/2024	15:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CNTX	Context Therapeutics Inc
02/05/2024	06:31	GlobeNewswire Inc.	Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76	NASDAQ:CNTX	Context Therapeutics Inc
02/05/2024	06:30	GlobeNewswire Inc.	Context Therapeutics Announces $100 Million Private Placement	NASDAQ:CNTX	Context Therapeutics Inc
01/04/2024	06:30	GlobeNewswire Inc.	Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	NASDAQ:CNTX	Context Therapeutics Inc
21/03/2024	06:43	GlobeNewswire Inc.	Context Therapeutics Reports Full Year 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
06/03/2024	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CNTX	Context Therapeutics Inc
07/02/2024	15:24	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CNTX	Context Therapeutics Inc
09/11/2023	15:15	GlobeNewswire Inc.	Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
31/10/2023	08:00	GlobeNewswire Inc.	Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76	NASDAQ:CNTX	Context Therapeutics Inc
27/09/2023	08:00	GlobeNewswire Inc.	Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	NASDAQ:CNTX	Context Therapeutics Inc
09/08/2023	15:10	GlobeNewswire Inc.	Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
01/08/2023	06:30	GlobeNewswire Inc.	Context Therapeutics to Participate in Two August 2023 Investor Conferences	NASDAQ:CNTX	Context Therapeutics Inc
20/06/2023	07:36	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:CNTX	Context Therapeutics Inc
31/05/2023	15:53	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:CNTX	Context Therapeutics Inc
10/05/2023	15:39	GlobeNewswire Inc.	Context Therapeutics Reports First Quarter 2023 Operating and Financial Results	NASDAQ:CNTX	Context Therapeutics Inc
03/04/2023	06:30	GlobeNewswire Inc.	Context Therapeutics to Participate in Two April 2023 Investor Conferences	NASDAQ:CNTX	Context Therapeutics Inc
27/03/2023	15:04	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:CNTX	Context Therapeutics Inc
22/03/2023	16:08	GlobeNewswire Inc.	Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates	NASDAQ:CNTX	Context Therapeutics Inc
15/03/2023	06:30	GlobeNewswire Inc.	Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023	NASDAQ:CNTX	Context Therapeutics Inc
14/02/2023	15:05	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:CNTX	Context Therapeutics Inc
06/02/2023	06:30	GlobeNewswire Inc.	Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer	NASDAQ:CNTX	Context Therapeutics Inc
31/01/2023	06:30	GlobeNewswire Inc.	Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer	NASDAQ:CNTX	Context Therapeutics Inc
09/01/2023	06:30	GlobeNewswire Inc.	Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers	NASDAQ:CNTX	Context Therapeutics Inc
04/01/2023	06:30	GlobeNewswire Inc.	Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones	NASDAQ:CNTX	Context Therapeutics Inc
08/12/2022	10:35	TipRanks	H.C. Wainwright Sticks to Their Buy Rating for Context Therapeutics (CNTX)	NASDAQ:CNTX	Context Therapeutics Inc
08/12/2022	06:30	GlobeNewswire Inc.	Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer	NASDAQ:CNTX	Context Therapeutics Inc
02/12/2022	05:15	TipRanks	Context Therapeutics (CNTX) Receives a Buy from H.C. Wainwright	NASDAQ:CNTX	Context Therapeutics Inc
29/11/2022	06:30	GlobeNewswire Inc.	Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors	NASDAQ:CNTX	Context Therapeutics Inc